‘Hope And Scientific Spillover’ – Cross-Atlantic HTA Alliance To Focus On Novel Benefits

An initiative run by health technology appraisal (HTA) bodies in the US, Canada and England is looking at how non-traditional treatment benefits, such as the value of hope and scientific spillover, can inform appraisals and understanding of a product’s value.

The first guidance to be delivered by the HEMA HTA collaboration will help HTAs analyze the value of drugs by considering novel treatment benefits.

More from Pink Sheet

More from Health Technology Assessment